1[1]Bukowski JF,Dascher CC,Das H.Alternative bisphosphonate targets and mechanisms of action.Biochem Biophys Res Commun,2005,328:746
2[2]Ferretti G,Fabi A,Carlini P,et al.Zoledronic -acidinduced circulating level modifications of angiogenic factors,metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.Oncology,2005,69:35
3[3]Clézardin P,Ebetino FH,Fournier PG.Bisphosphonates and cancer-induced bone disease:Beyond their antiresorptive activity.Cancer Res,2005,65:4971
4[4]Pavlakis N,Stockler M.Bisphosphonates for breast cancer.Cochrane Database Syst Rew,2005,CD003474.
5[5]Tripathy D,Lichinitzer M,Lazarev A,et al.Oral ibandronate for the treatment of metastatic bone disease in breast cancer:Efficacy and safety results from a randomized,double-blind,placebo-controlled trial.Ann Oncol,2004,15:743
6[6]Body JJ,Diel IJ,Bell R,et al.Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.Pain,2004,111:306
7[7]Heidenreich A,Ohlmann C,Body JJ.Ibandronate in metastatic bone pain.Semin Oncol,2004,31:67
8[8]Pecherstorfer M.Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.Expert Opin Pharmacother,2004,5:2341
9[9]Smith MR.Zoledronic acid to prevent skeletal complications in cancer:Corroborating the evidence.Cancer Treat Rew,2005,3:19
10[10]Saad F,Lipton A.Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.BJU Int,2005,96:964
7Coleman R E, Purohit O P. Osteoclast inhibition for the treatment of bone metastases[ J]. Cancer Treat Rev, 1993, 19(1) :79-103.
8Engel J, Eckel R, Aydemir U,et al. Determinant s and p rog-noses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys ,2003,55 : 1186-1195.
9Kimmel DB. Mechanism of action, pharmacokinetic andpharmacodynamic profile, and clinical applications of nitrogen - containing bisphospho- nates. J Dent Res,2007,86 : 1022-1033.
10Kleeberg UR, Schneider P. Medroxyprogesterone acetate in the treatment of metastasizing breast cancer. J Cancer Res, 1986,10 : 104-106.
